|
|
Prepublished online as a Blood First Edition Paper on November 7, 2002; DOI 10.1182/blood-2002-07-2298.
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2003, Vol. 101, No. 6, pp. 2363-2367
NEOPLASIA
A significant diffuse component predicts for inferior survival in
grade 3 follicular lymphoma, but cytologic subtypes do not predict
survival
Christine P. Hans,
Dennis
D. Weisenburger,
Julie M. Vose,
Lynette M. Hock,
James C. Lynch,
Patricia Aoun,
Timothy C. Greiner,
Wing C. Chan,
Robert G. Bociek,
Philip J. Bierman, and
James O. Armitage
From the Departments of Pathology and Microbiology,
Internal Medicine, and Preventive and Societal Medicine, University of
Nebraska Medical Center, Omaha, NE.
Grade 3 follicular lymphoma (FL3) is thought to have an aggressive
clinical course. On the basis of possible biologic differences, the new
World Health Organization (WHO) classification of lymphoma suggests further subdivision of FL3 into grades 3a and 3b and states
that the percentage of involvement by diffuse large B-cell lymphoma
(DLBCL) should also be reported. However, the clinical implications of
these features are unclear. Therefore, we studied 190 newly diagnosed
patients with lymph node-based FL3 who received anthracycline-containing combination chemotherapy. The follicular component was subclassified as grade 3a (FL3a) or grade 3b (FL3b) according to the WHO criteria, or as follicular large cleaved cell type
(FLC). The percentage of a diffuse component, if present, was also
recorded. Of the 190 cases, there were 107 FL3a (56%), 53 FL3b (28%),
and 30 FLC (16%) cases. Diffuse areas were seen in 72 cases (31 FL3a,
28 FL3b, and 13 FLC). There were no significant differences in the
clinical characteristics, overall survival, or event-free survival
between patients with grades FL3a, FL3b, or FLC. However, those cases
with a predominant diffuse component (> 50% diffuse) had a
significantly worse overall survival (P = .0037) and
event-free survival (P = .012). Therefore, we conclude that the subdivision of FL3 into cytologic subtypes does not appear to
be important clinically. However, patients with FL3 having a diffuse
component of more than 50% have an inferior survival that is similar
to the survival of those with DLBCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Chadburn, A. Chiu, J. Y. Lee, X. Chen, E. Hyjek, A. H. Banham, A. Noy, L. D. Kaplan, J. A. Sparano, K. Bhatia, et al.
Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034
J. Clin. Oncol.,
October 20, 2009;
27(30):
5039 - 5048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Johnson and R. D. Gascoyne
Gene expression signatures in follicular lymphoma: are they ready for the clinic?
Haematologica,
July 1, 2008;
93(7):
982 - 987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby
CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma
Clin. Cancer Res.,
January 15, 2007;
13(2):
388 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Ganti, D. D. Weisenburger, L. M. Smith, C. P. Hans, R. G. Bociek, P. J. Bierman, J. M. Vose, and J. O. Armitage
Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience
Ann. Onc.,
June 1, 2006;
17(6):
920 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Farinha, H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors, and R. D. Gascoyne
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Blood,
September 15, 2005;
106(6):
2169 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini, O. Mora, P. McLaughlin, P. Solal-Celigny, and on behalf of the Scientific Committee of the FLIPI
Does the FLIPI apply to grade 3 follicular lymphoma?
Blood,
June 15, 2005;
105(12):
4892 - 4893.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Kocjan
BEST PRACTICE No 185 Cytological and molecular diagnosis of lymphoma
J. Clin. Pathol.,
June 1, 2005;
58(6):
561 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bjorck, S. Ek, O. Landgren, M. Jerkeman, M. Ehinger, M. Bjorkholm, C. A. K. Borrebaeck, A. Porwit-MacDonald, and M. Nordenskjold
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
Blood,
April 1, 2005;
105(7):
2908 - 2915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne
Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
Hematology,
January 1, 2005;
2005(1):
299 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, R. D. Gascoyne, and K. Van Besien
Low-Grade Lymphoma
Hematology,
January 1, 2004;
2004(1):
203 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
